Krsnaa Diagnost. (KRSNAA)

Slow Grower

FairStock Score: 37/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Current Price₹575.3
Market Cap₹1,866.2 Cr
P/E Ratio18.62
ROCE12.52%
ROE9.47%
Dividend Yield0.35%
Profit Growth-19.13%
Debt/Equity0.55
Sales Growth21.3%
Promoter Holding27.11%
52-Week Range₹515 — ₹894.4
SectorHealthcare Services
Book Value₹302.22

Strengths

Concerns

AI Analysis

Krsnaa Diagnost is not a business that would get me excited. With a market cap of ₹2,061 Cr and a P/E of 25.65, the market is paying a full price for a company whose sales have shrunk by 3.47% and profits are down 23.66%. In the latest quarter, sales were ₹159 Cr and net profit ₹16 Cr, a margin of about 10%. But the trailing P/E suggests investors are assuming a rapid return to growth. I don't see evidence for that. The Piotroski F-Score of 3/9 is a serious red flag, indicating weak operating efficiency and deteriorating fundamentals. Graham would demand a margin of safety; at 2.33 times book with a 9.47% ROE, you are paying a premium for subpar returns. Debt-to-equity of 0.31 is manageable, and ROCE at 12.52% is okay, but not outstanding. Also, promoter holding of 27.11% is low; I like my captains to have a large ownership stake. The dividend yield of 0.43% offers no support. This looks like a slow grower at best, possibly a value trap if performance doesn't improve. I would need to see clear signs of revenue stabilization and an improving F-score before considering a nibble. As Benjamin Graham said, price is what you pay, value is what you get. Here, I'm not convinced value is present.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer